All In Biotech

Free tool

FAERS Monitor: Suprax

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203195 or its brand name (Suprax, Cefixime). Reports on generic versions are filed under their own applications.

Reports

3,061

Serious

2,619

86% of reports

Hospitalization

1,427

Death reported

212

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use299
  • drug ineffective292
  • pyrexia175
  • diarrhoea174
  • nausea173
  • pain158
  • malaise141
  • fatigue138
  • headache136
  • vomiting136
  • dyspnoea134
  • abdominal pain117
  • condition aggravated117
  • asthenia93
  • constipation92

Reports by year received

View as table
YearReports
200410
20055
20062
20078
20081
20099
201020
201141
201243
201344
201446
201555
2016102
201764
2018137
2019227
2020254
2021281
2022409
2023409
2024328
2025351
2026215

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,098 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pyrexiaSignal1753.53.0311
abdominal painSignal1173.52.9204
constipationSignal922.92.4114
condition aggravatedSignal1172.62.2120
off label useSignal2992.32.1240
malaiseSignal1412.21.994
vomiting1362.01.767
diarrhoea1741.91.670
pain1581.81.553
asthenia931.71.427
dyspnoea1341.61.433
drug ineffective2921.51.455
nausea1731.51.330
headache1361.51.322
fatigue1381.21.05

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.